Comparison of 5-fluorouracil with 5-fluorouracil, cyclophosphamide, and methotrexate in metastatic colorectal carcinoma

Cancer. 1975 Nov;36(5):1589-92. doi: 10.1002/1097-0142(197511)36:5<1589::aid-cncr2820360509>3.0.co;2-z.

Abstract

Thirty-eight patients with metastatic colorecal carcinoma were treated with 5-fluorouracil (5-FU), and 38 patients were treated with the combination of 5-FU, cyclophosphamide, and methotrexate. In terms of percent response, response duration, and survival there was no apparent difference between the two regimens. Combination chemotherapy was found to be effective in 6 of 16 patients refractory to treatment with 5-FU alone, but was associated with more morbidity.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / mortality
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / therapeutic use*
  • Drug Evaluation
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / therapeutic use*
  • Humans
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Neoplasm Metastasis
  • Rectal Neoplasms / drug therapy*
  • Rectal Neoplasms / mortality

Substances

  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate